Are changes in PSA kinetics potentially indicative of metastasis-free survival?

Posted on October 27, 2011 by Sitemaster

Researchers at Johns Hopkins have provided data to support the hypothesis that, in men being treated with novel, non-hormonal agents for non-metastatic, non-castrate, biochemically recurrent prostate cancer after first-line therapy, changes in PSA kinetics may be indicative of metastasis-free survival. … READ MORE …

Filed under: Drugs in development, Management, Treatment | Tagged: , , , , | Leave a Comment »

Potential surrogate endpoints for prostate cancer-specific survival

Posted on March 14, 2009 by Sitemaster

There have been several attempts to clearly define surrogate endpoints for prostate cancer-specific survival that could be used to shorten the length of clinical trials investigating the merits of specific forms of treatment for prostate cancer. A new analysis of data from the 1,554-patient RTOG 92-02 trial has further explored two such possibilities. … READ MORE …

Filed under: Drugs in development, Management, Treatment | Tagged: , , | Leave a Comment »

Follow

Get every new post delivered to your Inbox.

Join 832 other followers